Glenmark Pharmaceuticals Ltd Quarterly Results
Q1 FY26-27 Results Summary
Revenue
The revenue stands at ₹4,018.48 crore, reflecting a quarter-on-quarter *(QoQ) increase of 6.57 per cent from ₹3,770.59 crore. This corresponds to a year-on-year *(YoY) growth of 23.10 per cent.
Operating Profit
Operating Profit stands at ₹804.79 crore, reflecting a quarter-on-quarter *(QoQ) increase of 106.78 per cent from ₹389.20 crore. This corresponds to a year-on-year *(YoY) growth of 212.79 per cent.
PBDT
PBDT stands at ₹816.55 crore, reflecting a quarter-on-quarter *(QoQ) increase of 52.44 per cent from ₹535.67 crore. This corresponds to a year-on-year *(YoY) growth of 262.11 per cent.
Profit Before Tax
Profit Before Tax stands at ₹643.38 crore, reflecting a quarter-on-quarter *(QoQ) increase of 65.92 per cent from ₹387.76 crore. This corresponds to a year-on-year *(YoY) growth of 573.20 per cent.
Net Profit
Net Profit stands at ₹482.82 crore, reflecting a quarter-on-quarter *(QoQ) increase of 60.24 per cent from ₹301.31 crore. This represents a 927.93 per cent year-on-year *(YoY) growth for the same year.
- YoY compares a quarter to the same period last year, and QoQ compares it to the previous quarter.
Glenmark Pharmaceuticals Ltd News
Glenmark Pharmaceuticals Ltd Earnings
- YOY
- QOQ
Glenmark Pharmaceuticals Ltd Earning Charts
Revenue from Operations
in ₹ cr
EBITDA
in ₹ cr
Profit before Tax
in ₹ cr
Net Profit
in ₹ cr
Glenmark Pharmaceuticals Ltd Research Reports
Glenmark Pharmaceuticals Ltd Financial Reports
Glenmark Pharmaceuticals Ltd Stock Prices Compare with Peers
| Company | 1 Day | 1 Week | 1 month | 3 month | 6 month | 1 Year |
|---|---|---|---|---|---|---|
| Glenmark Pharma. | -1.07% | 3.54% | -1.21% | 5.94% | -3.54% | 21.60% |
| Mankind Pharma | 1.12% | 8.11% | -1.51% | 0.58% | 10.09% | 3.62% |
| Aurobindo Pharma | 1.38% | 5.52% | 0.17% | 5.46% | 21.95% | 44.88% |
| Lupin | 0.55% | 3.03% | -0.99% | -15.45% | -14.55% | 1.17% |
| Alkem Lab | 1.49% | 1.36% | -2.19% | -9.82% | -4.30% | -8.92% |
| Biocon | 0.00% | 7.73% | -5.10% | -16.78% | -2.33% | -6.68% |
| Abbott India | -1.59% | 1.47% | -4.62% | -8.16% | 0.66% | -12.00% |
Company Info
Company Information
Chairman / Executive Director / M D / Promoter : Glenn Saldanha
Executive Director (Corporate) : Cheryl Pinto
Executive Director & Group CFO : Anurag Mantri
Independent Non Exe. Director : Sona Saira Ramasastry
Independent Non Exe. Director : Dipankar Bhattacharjee
Independent Non Exe. Director : V R Iyer
Independent Non Exe. Director : Pradeep Kumar Sinha
Independent Non Exe. Director : Patricia Andrews
Non Executive Director : B E Saldanha
Company Secretary / Compliance Officer : Rashmi Khandelwal.